TP53 Mutations and RNA Binding Protein Musashi 2 Drive Resistance to PRMT5-Targeted Therapy in B-Cell Lymphoma

Ingrid Tatiana Erazo,Chiara M Evans,Daniel Zakheim,Karen L Chu,Olena Barbash,Alice Yunsi Refermat,Connie Lee Batlevi,Anas Younes,Michael G Kharas

Blood（2021）

引用 4|浏览17

暂无评分

摘要

PRMT5 catalyzes the arginine symmetric demethylation of histone and non-histone proteins. PRMT5 is overexpressed in lymphoma and plays a key role in lymphomagenesis through the repression of several tumor suppressors, including P53, while promoting the expression of lymphoma-drivers, such as c-MYC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要